Litcius/Paper detail

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Pau Abrisqueta, Eva González‐Barca, Carlos Panizo, José María Arguiñano Pérez, Fiona Miall, Mariana Bastos‐Oreiro, Ana Triguero, Lalita Banerjee, Andrew McMillan, Erlene Seymour, Jamie Hirata, Jayson de Guzman, Sunil Sharma, Hyun Yong Jin, Lisa Musick, Catherine Diefenbach

2024The Lancet Haematology16 citationsDOIOpen Access PDF

Topics & Concepts

MedicineLenalidomideRituximabDiffuse large B-cell lymphomaInternal medicineRefractory (planetary science)LymphomaOncologyCohortPhases of clinical researchClinical trialMultiple myelomaAstrobiologyPhysicsLymphoma Diagnosis and TreatmentCAR-T cell therapy researchHER2/EGFR in Cancer Research